Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil for clitoral blood flow in menopausal hypertensive women with sexual interest and arousal disorder
2016-001011-21Phase 2Terminated
- Sponsor
- Litaphar
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tadalafil in female sexual arousal disorder (FSAD), sponsored by Litaphar. Primary endpoint: Change in clitoral peak systolic velocity. Started Apr 2016; status: terminated.
02
Drugs
tadalafil
03
Conditions
female sexual arousal disorder (FSAD)
Beyond the preview
Go deeper on 2016-001011-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001011-21.